Meeder Asset Management Inc. Buys 7,336 Shares of Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX)

Meeder Asset Management Inc. raised its stake in Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) by 163.1% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 11,833 shares of the biopharmaceutical company’s stock after buying an additional 7,336 shares during the period. Meeder Asset Management Inc.’s holdings in Catalyst Pharmaceuticals were worth $247,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also recently made changes to their positions in the stock. O Shaughnessy Asset Management LLC increased its stake in Catalyst Pharmaceuticals by 76.2% in the fourth quarter. O Shaughnessy Asset Management LLC now owns 19,349 shares of the biopharmaceutical company’s stock valued at $404,000 after acquiring an additional 8,367 shares during the last quarter. Arrowstreet Capital Limited Partnership boosted its holdings in shares of Catalyst Pharmaceuticals by 131.4% in the 4th quarter. Arrowstreet Capital Limited Partnership now owns 698,152 shares of the biopharmaceutical company’s stock worth $14,570,000 after purchasing an additional 396,506 shares in the last quarter. Cornercap Investment Counsel Inc. purchased a new position in shares of Catalyst Pharmaceuticals in the 4th quarter worth about $494,000. Horizon Investment Services LLC increased its position in shares of Catalyst Pharmaceuticals by 167.1% during the 4th quarter. Horizon Investment Services LLC now owns 39,524 shares of the biopharmaceutical company’s stock valued at $825,000 after purchasing an additional 24,724 shares during the last quarter. Finally, Pictet Asset Management Holding SA raised its holdings in shares of Catalyst Pharmaceuticals by 27.4% during the 4th quarter. Pictet Asset Management Holding SA now owns 15,969 shares of the biopharmaceutical company’s stock valued at $333,000 after buying an additional 3,431 shares in the last quarter. Hedge funds and other institutional investors own 79.22% of the company’s stock.

Insider Buying and Selling

In other news, insider Brian Elsbernd sold 62,975 shares of the business’s stock in a transaction that occurred on Monday, March 3rd. The stock was sold at an average price of $22.98, for a total value of $1,447,165.50. Following the sale, the insider now directly owns 188,564 shares of the company’s stock, valued at $4,333,200.72. The trade was a 25.04 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Also, insider Gary Ingenito sold 44,904 shares of the company’s stock in a transaction that occurred on Wednesday, March 5th. The stock was sold at an average price of $22.09, for a total value of $991,929.36. Following the completion of the sale, the insider now owns 68,873 shares in the company, valued at $1,521,404.57. The trade was a 39.47 % decrease in their position. The disclosure for this sale can be found here. 11.00% of the stock is owned by insiders.

Analyst Ratings Changes

Several analysts have issued reports on CPRX shares. StockNews.com raised Catalyst Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research note on Friday, February 28th. Robert W. Baird increased their target price on shares of Catalyst Pharmaceuticals from $28.00 to $32.00 and gave the company an “outperform” rating in a report on Monday, March 3rd. Bank of America reissued a “buy” rating and issued a $30.00 price target on shares of Catalyst Pharmaceuticals in a research note on Thursday, January 9th. HC Wainwright restated a “buy” rating and set a $35.00 price target on shares of Catalyst Pharmaceuticals in a research report on Friday, February 28th. Finally, Baird R W upgraded Catalyst Pharmaceuticals to a “strong-buy” rating in a report on Monday, February 3rd. Seven investment analysts have rated the stock with a buy rating and two have issued a strong buy rating to the company. Based on data from MarketBeat, the company currently has a consensus rating of “Buy” and a consensus target price of $32.29.

Catalyst Pharmaceuticals Stock Performance

NASDAQ CPRX opened at $24.25 on Tuesday. The stock has a 50 day simple moving average of $22.69 and a two-hundred day simple moving average of $21.86. Catalyst Pharmaceuticals, Inc. has a fifty-two week low of $14.47 and a fifty-two week high of $26.16. The stock has a market cap of $2.95 billion, a P/E ratio of 20.55, a price-to-earnings-growth ratio of 3.31 and a beta of 0.84.

Catalyst Pharmaceuticals Company Profile

Catalyst Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients.